CSIMarket
 



Amag Pharmaceuticals inc   (AMAG)
Other Ticker:  
 
 



 

What are Amag Pharmaceuticals Inc's Business Segments?



Amag Pharmaceuticals Inc is a biopharmaceutical company that focuses on research, development, and commercialization of products that address unmet medical needs. The company's segments, products, and services are described below:

Segments:

1. Feraheme: This segment of Amag Pharmaceuticals focuses on developing and commercializing Feraheme, an intravenous (IV) iron replacement therapy used to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is also used to treat IDA in adult patients who are intolerant to oral iron or who have non-dialysis dependent CKD.

2. Intrarosa: This segment of Amag Pharmaceuticals focuses on developing and commercializing Intrarosa, a locally administered, once-daily, vaginal hormone replacement therapy used to treat moderate to severe dyspareunia (painful sexual intercourse) in women who are postmenopausal.

3. Vyleesi: This segment of Amag Pharmaceuticals focuses on developing and commercializing Vyleesi, also known as bremelanotide, a subcutaneous injection used to treat premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Products:

1. Feraheme: Feraheme is an IV iron replacement therapy used to treat IDA in adult patients with CKD. It is a colloidal iron hydroxide complex that is indicated for the treatment of iron deficiency anemia in patients with CKD.

2. Intrarosa: Intrarosa is a locally administered, once-daily, vaginal hormone replacement therapy used to treat moderate to severe dyspareunia (painful sexual intercourse) in women who are postmenopausal. It is a DHEA prodrug that is metabolized in the body to form androgens and estrogens.

3. Vyleesi: Vyleesi is a subcutaneous injection used to treat premenopausal women with acquired, generalized HSDD. It is a melanocortin agonist that works by stimulating the melanocortin receptors in the brain associated with sexual desire.

Services:

1. Patient Access Services: Amag Pharmaceuticals offers patient access services to help patients access its products. These services include reimbursement assistance, financial assistance programs, and co-pay assistance programs.

2. Medical Affairs: Amag Pharmaceuticals has a medical affairs department that provides scientific and medical information to healthcare professionals, patients, and other stakeholders.

3. Clinical Development: Amag Pharmaceuticals has a clinical development department that conducts research and clinical trials to evaluate the safety and efficacy of its products. The company invests significant resources in developing and testing its products to ensure they meet regulatory standards and address unmet medical needs.
   

Amag Pharmaceuticals Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2020)
%
(Profit Margin)
Total 93.11 19.35 20.78 %

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2020)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2020)
Q/Q Income
%
Total 10.67 % 76.49 % - 11994.38 %

To get more information on Amag Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com